Last August, the U.S. Food and Drug Administration began testing MDMA (ecstasy) for treating post-traumatic stress disorder. The FDA also granted MDMA breakthrough therapy status to expedite the approval process by making it easier for drugmakers to begin clinical trials. Recently, MDMA passed phase 2 of the FDA’s four-phase drug-approval process. Although phase 3 requires … Continue reading FDA Moves Closer to Approving Ecstasy